Group 1 - MSCI announced its quarterly index adjustments for February 2026, effective after the market close on February 27 [2][3] - The MSCI Global Small Cap Index will include 21 new stocks from the China region, such as Anjuke Food (603345), AutoHome (ATHM.US), and Baiaosaitu (02315) [2][3] - The adjustments also include the addition of stocks from Hong Kong, such as Champion REIT (02778) and Longjiang Life Science Technology (00755) [3][4] Group 2 - Stocks removed from the MSCI Global Small Cap Index include Yasheng Service (03319), BOE Technology Group (00710), and Chaince Digital (CD.US) [2][3] - In Hong Kong, stocks like Cafe de Coral (00341) and SuperX AI (SUPX.US) were also removed from the index [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 艾迪康控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 09860 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 725,643,291 1,617,000 727,260,291 增加 / 減少 (-) 0 0 本月底結存 725,643,291 1,617,000 727,260,291 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） | | 根據《主板上市規則》第1 ...

Group 1 - GIC Private Limited increased its stake in Eddycon Holdings (09860.HK) by purchasing 891,500 shares at an average price of HKD 5.00 per share, totaling approximately HKD 4.4575 million [1][3] - Following this transaction, GIC's total shareholding in Eddycon Holdings rose to 36,837,500 shares, which represents an increase in ownership from 4.94% to 5.07% [1][3]

Core Viewpoint - GIC Private Limited has increased its stake in Adicon Holdings (09860), acquiring 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% ownership, triggering a mandatory disclosure [1] Group 1: Company Developments - Adicon's strategic focus on AI in medical testing has garnered significant market attention, transitioning from traditional models to intelligent and ecological approaches [1] - The company signed a cooperation agreement with Huawei Cloud in December, marking the beginning of a new chapter in smart healthcare powered by AI technology [1] - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million by November 2025, which will enhance its capabilities in drug development and diagnostics [1] Group 2: Market Reactions - Jefferies has issued a "Buy" rating for Adicon Holdings with a target price of HKD 12.60, citing the company's strategic moves in AI medical testing and the acquisition of Crown Bioscience as key factors [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical sector and solidifying its position as a leading quality asset in the industry [2]

Group 1 - GIC Private Limited increased its stake in Adicon Holdings (09860) by purchasing 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% of the company, officially triggering the takeover threshold [1] - Adicon's strategic focus on AI in medical testing has garnered significant market attention, as the company transitions its medical testing services from traditional models to intelligent and ecological approaches [1] - In December 2022, Adicon signed a cooperation agreement with Huawei Cloud to initiate a new chapter in smart healthcare powered by AI technology, showcasing its technological iteration path and forward-looking layout in AI medical innovation applications [1] Group 2 - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million, which is expected to significantly enhance the company's comprehensive strength in the drug development and diagnostic value chain [1] - Jefferies Financial has issued a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, citing the company's strategic layout in AI medical testing and the acquisition of Crown Bioscience as major initiatives to strengthen its position [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical field and further solidifying its market position as a leading quality asset in the industry [2]

Group 1 - The stock of Eddie Holdings (9860.HK) experienced a significant decline after a previous surge, dropping over 12% to 5.16 HKD, which is more than a 30% decrease from its intraday high of 7.4 HKD yesterday [2]

Core Viewpoint - Adicon Holdings (09860) has seen a significant stock price increase, rising over 37% in early trading and currently up 21.85% to HKD 6.58, with a trading volume of HKD 68.54 million [1] Group 1: Acquisition Details - In November of last year, Adicon announced the acquisition of 100% equity in Crown Bioscience for USD 204 million, expected to be completed by mid-2026 [1] - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and serving over 1,100 clients, including the top 20 pharmaceutical companies [1] Group 2: Strategic Implications - According to the latest report from Jefferies, Adicon's strategic positioning in AI medical testing and the acquisition of Crown Bioscience will significantly enhance its comprehensive strength in the drug development and diagnostic value chain [1] - The acquisition is expected to substantially improve Adicon's capabilities in preclinical and translational research, leveraging Crown's extensive data assets and bioinformatics expertise to further solidify its industry position [1] - Post-acquisition, it is anticipated that approximately 23% of Adicon's revenue will come from overseas markets [1]

Core Viewpoint - The report by Jefferies gives a "Buy" rating to Adicon Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience, which will enhance its capabilities in drug development and diagnostics [1][5]. Group 1: AI Strategy - Adicon's AI strategy is built around three main pillars: 1. An AI-assisted pathology reading system that increases slide reading efficiency by 6-7 times compared to manual methods, with quality control features for error detection [1][5]. 2. The launch of a generative AI laboratory assistant named "Aixiaoyi" for clinicians and a clinical large language model "Wenyi" developed in collaboration with Huawei, integrated into clinical workflows for report quality control, flow cytometry analysis, and patient intelligent diagnosis portals [1][5]. 3. Completion of a 20-year integration, governance, and cleansing of precision medicine testing data, with ongoing exploration of commercialization opportunities in areas like commercial insurance. The company currently performs approximately 10 million AI-assisted image interpretations annually [1][5]. Group 2: Acquisition of Crown Bioscience - Adicon announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2][6]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and deep expertise in CDX models and biomarker solutions, serving over 1,100 clients, including the top 20 global pharmaceutical companies [2][6]. - The acquisition is expected to significantly enhance Adicon's capabilities in preclinical and translational research, further solidifying its industry position through Crown's rich data assets and bioinformatics expertise. Post-acquisition, approximately 23% of Adicon's revenue is anticipated to come from international markets [2][6].

Core Viewpoint - The report from Jefferies gives a "Buy" rating for ADICON Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience, which will enhance its capabilities in drug development and diagnostics [1][2]. Group 1: AI Strategy - ADICON's AI strategy is built around three main pillars: the AI-assisted pathology reading system, which increases reading efficiency by 6-7 times compared to manual methods and includes quality control features for error correction [1]. - The company has launched generative AI tools for clinical doctors, such as "Aixiaoyi" and a clinical large language model developed in collaboration with Huawei, which are integrated into diagnostic workflows for quality control and patient diagnosis [1]. - ADICON has completed a 20-year integration, governance, and cleansing of precision medicine testing data and is exploring commercialization opportunities in areas like commercial insurance, currently performing approximately 10 million AI-assisted image interpretations annually [1]. Group 2: Acquisition of Crown Bioscience - ADICON announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and a strong presence in CDX models and biomarker solutions, serving over 1,100 clients, including the top 20 pharmaceutical companies [2]. - The acquisition is expected to significantly enhance ADICON's capabilities in preclinical and translational research, with Crown's data assets and bioinformatics expertise further solidifying its industry position, and it is anticipated that around 23% of ADICON's revenue will come from international markets post-acquisition [2].

Core Viewpoint - The report from Jefferies gives a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience as key factors to enhance its capabilities in drug development and diagnostics value chain [1][2]. Group 1: AI Strategy - Adicon's AI strategy is built around three main pillars: the AI-assisted pathology reading system, which increases reading efficiency by 6-7 times compared to manual methods and includes quality control features for error correction [1]. - The company has launched generative AI tools for clinical doctors, such as "Aixiaoyi" and a clinical large language model developed in collaboration with Huawei, which are integrated into diagnostic workflows for quality control and patient diagnosis [1]. - Adicon has completed the integration, governance, and cleaning of 20 years of precision medicine testing data and is exploring commercialization opportunities in areas like commercial insurance, currently performing approximately 10 million AI-assisted image interpretations annually [1]. Group 2: Acquisition of Crown Bioscience - Adicon announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and serving over 1,100 clients, including the top 20 pharmaceutical companies [2]. - The acquisition is expected to significantly enhance Adicon's capabilities in preclinical and translational research, with approximately 23% of its revenue projected to come from overseas markets post-transaction [2].